Z 350

Drug Profile

Z 350

Latest Information Update: 07 May 2004

Price : $50

At a glance

  • Originator Zeria
  • Class Indoles; Piperazines
  • Mechanism of Action Alpha 1 adrenergic receptor antagonists; Cholestenone 5-alpha reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Benign prostatic hyperplasia

Most Recent Events

  • 07 May 2004 Discontinued - Preclinical for Benign prostatic hyperplasia in Japan (PO)
  • 09 Dec 2003 No development reported - Preclinical for Benign prostatic hyperplasia in Japan (PO)
  • 17 Sep 2001 A preclinical study has been added to the Men's Health pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top